Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714630 | 0.98 | HIF1A (0.43) | HIF1ACAMK2ATSHRKDM4EGAA | |
| SCHEMBL9311929 | 0.88 | HIF1A (0.43) | HIF1ACAMK2ATSHRACEMAPT | |
| SCHEMBL11861055 | 0.87 | HIF1A (0.53) | HIF1ATSHRFNTAFNTBACE | |
| SCHEMBL1713729 | 0.86 | GPR84 (0.42) | HIF1ACAMK2ATSHRKDM4EGAA | |
| SCHEMBL1714397 | 0.86 | GPR84 (0.42) | HIF1ACAMK2ATSHRKDM4EGAA | |
| SCHEMBL12855872 | 0.84 | GPR84 (0.46) | HIF1ATSHRKDM4EGAAFNTA | |
| SCHEMBL30497477 | 0.84 | GPR84 (0.46) | HIF1ATSHRKDM4EGAAFNTA | |
| SCHEMBL27820579 | 0.82 | — | — | |
| SCHEMBL29505046 | 0.82 | CAMK2A (0.56) | CAMK2ATSHRKDM4EGAAFNTA | |
| SCHEMBL10406439 | 0.79 | HIF1A (0.50) | HIF1ATSHRACEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368604-B2 | Method for the production of acylphosphine oxides | BASF AKTIENGESELLSCHAFT (DE) | 2008-05-06 | — | — | US | claimed |
| EP-1546163-B1 | METHOD FOR THE PRODUCTION OF ACYLPHOSPHINE OXIDES | BASF AG (DE) | 2006-07-12 | — | — | EP | claimed |
| US-20060052636-A1 | Method for the production of acylphosphine oxides | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-09 | — | — | US | claimed |
| CN-107001654-B | Method for curing curable composition | 巴斯夫欧洲公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10577471-B2 | Method for curing curable compositions | BASF SE (DE) | 2020-03-03 | — | — | US | disclosed |
| EP-3201261-B1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2018-12-12 | — | — | EP | disclosed |
| US-20180148554-A9 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2018-05-31 | — | — | US | disclosed |
| US-9840635-B2 | Binding agent systems | CONSTRUCTION RESEARCH & TECHNOLOGY, GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170306118-A1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3201261-A1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3066161-B1 | COATINGS FOR USE AS ADHESIVE | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-20060052636-A1 | Method for the production of acylphosphine oxides | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1613638-A2 | METHOD FOR PRODUCING ACYLPHOSPHINE OXIDE SOLIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050222294-A1 | Acyl- and bisacylphosphine derivatives | IGM GROUP B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| WO-2005057286-A1 | COATING MATERIALS CONTAINING α-(1'-HYDROXYALKYL)ACRYLATES | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-23 | — | — | WO | disclosed |
| WO-2004094439-A2 | METHOD FOR THE PRODUCTION OF ACYLPHOSPHINES | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004087723-A2 | METHOD FOR PRODUCING ACYLPHOSPHINE OXIDE SOLIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-14 | — | — | WO | disclosed |
| US-20040116702-A1 | Alkoxylated acyl-and bisacylphoshine derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003068783-A1 | ALKOXYLATED ACYL- AND BISACYLPHOSPHINE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068785-A1 | MONO- AND BIACYLPHOSPHINE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052636-A1 | Method for the production of acylphosphine oxides | AGPAT5, PNPO, PHOSPHO1 | HIF1A 4444/4885CAMK2A 1425/4885TSHR 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.